BiotechTube

Sebetralstat

Pre-clinicalActive
1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

— → —

NCT ID
NCT07216378

About Sebetralstat

Sebetralstat is a pre-clinical stage product being developed by KalVista Pharmaceuticals for Hereditary Angioedema. The current trial status is active. This product is registered under clinical trial identifier NCT07216378. Target conditions include Hereditary Angioedema.

What happened to similar drugs?

2 of 20 similar drugs in Hereditary Angioedema were approved

Approved (2) Terminated (0) Active (18)
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Canakinumab + PlaceboNovartisPhase 3
🔄EmicizumabRochePhase 3
🔄NitisinoneSwedish Orphan BiovitrumPhase 3

Hype Score Breakdown

Clinical
3
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06628713Pre-clinicalCompleted
NCT07216378Pre-clinicalActive

Competing Products

20 competing products in Hereditary Angioedema

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
21
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Deferasirox FCTNovartisPhase 2
27
Canakinumab + PlaceboNovartisPhase 3
40
IlarisNovartisPre-clinical
33
Standard of Care for Haemophilia ARochePre-clinical
26
EmicizumabRochePhase 3
40
TafamidisPfizerPre-clinical
26
tafamidisPfizerPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPhase 1
29
NitisinoneSwedish Orphan BiovitrumPre-clinical
18